

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7295145

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
TAKEDA PHARMACEUTICALS USA, INC.	07/31/2021
RECEIVING PARTY DATA	
Name:	TAKEDA PHARMACEUTICAL COMPANY LIMITED
Street Address:	1-1 DOSHOMACHI 4-CHOME
Internal Address:	CHUO-KU, OSAKA-SHI
City:	OSAKA
State/Country:	JAPAN
Postal Code:	541-0045
PROPERTY NUMBERS Total: 4	
Property Type	Number
Application Number:	62814210
Application Number:	62826523
Application Number:	16810770
PCT Number:	US2021270
CORRESPONDENCE DATA	
Fax Number:	(415)442-1001
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	14154421000
Email:	jennifer.black@morganlewis.com
Correspondent Name:	MORGAN, LEWIS & BOCKIUS LLP
Address Line 1:	ONE MARKET, SPEAR STREET TOWER
Address Line 4:	SAN FRANCISCO, CALIFORNIA 94105
ATTORNEY DOCKET NUMBER:	118459-5009
NAME OF SUBMITTER:	JENNIFER C. BLACK
SIGNATURE:	/Jennifer C. Black/
DATE SIGNED:	04/24/2022
Total Attachments: 7	
source=EXECUTED_Doc 1_Master_Assignment (TPUSA to TPC)#page1.tif	

source=EXECUTED_Doc 1_Master_Assignment (TPUSA to TPC)#page2.tif
source=EXECUTED_Doc 1_Master_Assignment (TPUSA to TPC)#page3.tif
source=EXECUTED_Doc 1_Master_Assignment (TPUSA to TPC)#page4.tif
source=EXECUTED_Doc 1_Master_Assignment (TPUSA to TPC)#page5.tif
source=EXECUTED_Doc 1_Master_Assignment (TPUSA to TPC)#page6.tif
source=EXECUTED_Doc 1_Master_Assignment (TPUSA to TPC)#page7.tif

PATENT ASSIGNMENT

WHEREAS, Takeda Pharmaceuticals USA, Inc., a corporation under the laws of the State of Delaware, USA and having a place of business at The Corporation Trust Center, 1209 Orange Street, Wilmington, Delaware 19801, USA (the "Assignor"), is the owner of the patent(s) and application(s) identified in attached Schedule A ("the Patent(s)"); and

WHEREAS, Takeda Pharmaceutical Company Limited, a public stock corporation organized under the laws of Japan and having a place of business at 1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka, Japan (the "Assignee"), is desirous of acquiring the Patent(s), and related invention(s) thereof;

NOW, THEREFORE, effective on the 31st day of July, 2021, for good and valuable consideration, the receipt of which is hereby acknowledged, Assignor has sold, assigned and transferred and by these presents does sell, assign, and transfer unto said Assignee, and Assignee's successors and assigns, all right, title and interest in and to the Patent(s), and the invention(s) disclosed and claimed therein, and any Letters Patent which may hereafter be granted on the same in the United States and all countries throughout the world including any reissues, divisions, renewals, continuations in whole or in part, substitutions, conversions, reexaminations, prolongations, provisionals or extensions thereof, as well as rights to any and all existing causes of action and the right to past damages associated therewith, and all rights under the Paris Convention for the Protection of Industrial Property, the same to be held and enjoyed by Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, to the full end of the term or terms for which Letters Patent or Patent(s) may be granted as fully and entirely as the same would have been held and enjoyed by Assignor had this sale and assignment not been made.

Assignor hereby grants the Assignee the right to update the bibliographic information found in the attached Schedule A from time to time, including but not limited to adding the patent application numbers and patent numbers for those filings that fall under the scope of the above grant, such that this Agreement can be recorded with the respective global patent offices and ministries.

Assignee hereby grants a limited power of attorney for the purpose of recording this assignment in the United States and all other countries throughout the world to the practitioners listed on the power of attorney attached herewith and further grant the power to insert on this Assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office or any other patent office worldwide for recordation of this document.

IN WITNESS WHEREOF, Assignor, by its duly authorized officer, has executed this assignment in Boston, Massachusetts, USA as of this 31st day of July, 2021.

ON BEHALF OF Takeda Pharmaceuticals USA, Inc.

By: *Lillian Hielt*


Printed Name: Lillian Hielt
Title: IP Therapeutic Area Head, Oncology

STATE OF MASSACHUSETTS §
 §
COUNTY OF MIDDLESEX §

On this 31st day of July 2021, before me, Noreen Buckley, Notary Public, personally appeared Lillian Hielt, personally known to me or identified by me to be the person whose name is subscribed to the within instrument and evidenced to me that they executed the same in their authorized capacity, and that by their signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.

WITNESS my hand and official seal.


Noreen Buckley
Noreen Buckley
NOTARY PUBLIC
My Commission Expires: 28 September 2023



NOREEN BUCKLEY
Notary Public
Commonwealth of Massachusetts
My Commission Expires
September 28, 2023

IN WITNESS WHEREOF, Assignee, by its duly authorized officer, has executed this assignment in Boston, Massachusetts, USA
as of this 31st day of July 2021.

ON BEHALF OF Takeda Pharmaceutical Company Limited


By: 

Printed Name: Patrick Eagleman
Title: Authorized Signatory, Vice President Intellectual Property

STATE OF MASSACHUSETTS §
 §
COUNTY OF MIDDLESEX §


On this 31st day of July 2021, before me, NOREEN BUCKLEY, Notary Public, personally appeared Patrick Eagleman, personally known to me or identified by me to be the person whose name is subscribed to the within instrument and evidenced to me that they executed the same in their authorized capacity, and that by their signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.

WITNESS my hand and official seal.





Noreen Buckley
NOTARY PUBLIC
My Commission Expires: 28 September 2023

 **NOREEN BUCKLEY**
Notary Public
Commonwealth of Massachusetts
My Commission Expires
September 28, 2023

Schedule A

Status	Country	Application No.	Filed Date	Patent No.	Assignor
Pending	Algeria	200193	9/6/2018		Maverick Therapeutics, Inc.
Pending	Argentina	P180102562	9/10/2018		Maverick Therapeutics, Inc.
Pending	Australia	2017229687	3/8/2017		Maverick Therapeutics, Inc.
Pending	Australia	2018328291	9/6/2018		Maverick Therapeutics, Inc.
Pending	Brazil	1120180681890	3/8/2017		Maverick Therapeutics, Inc.
Pending	Brazil	1120200045438	9/6/2018		Maverick Therapeutics, Inc.
Pending	Canada	3016165	3/8/2017		Maverick Therapeutics, Inc.
Pending	Canada	3075034	9/6/2018		Maverick Therapeutics, Inc.
Pending	Chile	202000570	9/6/2018		Maverick Therapeutics, Inc.
Pending	China	201780028480.4	3/8/2017		Maverick Therapeutics, Inc.
Pending	China	201880072182.X	9/6/2018		Maverick Therapeutics, Inc.
Pending	China	201980058849.5	8/9/2019		Maverick Therapeutics, Inc.
Inactive	China	201880072457.X	9/6/2018		Maverick Therapeutics, Inc.
Pending	Colombia	NC2020/0004288	9/6/2018		Maverick Therapeutics, Inc.
Pending	Ecuador	SENADI-2020-21323	9/6/2018		Maverick Therapeutics, Inc.
Pending	Egypt	429/2020	9/6/2018		Maverick Therapeutics, Inc.
Pending	EPO	17764037.2	3/8/2017		Maverick Therapeutics, Inc.
Pending	EPO	18782832.2	9/6/2018		Maverick Therapeutics, Inc.
Pending	EPO	19769286.8	8/9/2019		Maverick Therapeutics, Inc.
Inactive	EPO	18782834.8	9/6/2018		Maverick Therapeutics, Inc.
Pending	Eurasian Patent Office	202090671	9/6/2018		Maverick Therapeutics, Inc.
Pending	Hong Kong	19125011.7	3/8/2017		Maverick Therapeutics, Inc.
Pending	Hong Kong	62020022862	9/6/2018		Maverick Therapeutics, Inc.
Inactive	Hong Kong	62020022368.8	9/6/2018		Maverick Therapeutics, Inc.
Pending	India	201817036773	3/8/2017		Maverick Therapeutics, Inc.

Schedule A

Status	Country	Application No.	Filed Date	Patent No.	Assignor
Pending	India	202017015113	9/6/2018		Maverick Therapeutics, Inc.
Pending	Indonesia	PID201807901	3/8/2017		Maverick Therapeutics, Inc.
Pending	Indonesia	P00202002600	9/6/2018		Maverick Therapeutics, Inc.
Pending	Israel	261432	3/8/2017		Maverick Therapeutics, Inc.
Pending	Israel	273119	9/6/2018		Maverick Therapeutics, Inc.
Pending	Japan	2018-547940	3/8/2017		Maverick Therapeutics, Inc.
Pending	Japan	2020-513686	9/6/2018		Maverick Therapeutics, Inc.
Pending	Japan	2021-506644	8/9/2019		Maverick Therapeutics, Inc.
Inactive	Japan	2020-513722	9/6/2018		Maverick Therapeutics, Inc.
Pending	Korea	10-2018-7029014	3/8/2017		Maverick Therapeutics, Inc.
Pending	Korea	10-2020-7010104	9/6/2018		Maverick Therapeutics, Inc.
Pending	Malaysia	PI 2020001225	9/6/2018		Maverick Therapeutics, Inc.
Pending	Mexico	MX/a/2018/010824	3/8/2017		Maverick Therapeutics, Inc.
Pending	Mexico	MX/a/2020/002667	9/6/2018		Maverick Therapeutics, Inc.
Pending	New Zealand	763198	9/6/2018		Maverick Therapeutics, Inc.
Pending	Peru	334-2020	9/6/2018		Maverick Therapeutics, Inc.
Pending	Philippines	1-2020-500474	9/6/2018		Maverick Therapeutics, Inc.
Inactive	Puerto Rico	62/305,092	3/8/2016		Maverick Therapeutics, Inc.
Pending	Russia	2018134949	3/8/2017		Maverick Therapeutics, Inc.
Pending	Singapore	11201807548S	3/8/2017		Maverick Therapeutics, Inc.
Pending	Singapore	SG11202002089RA	9/6/2018		Maverick Therapeutics, Inc.
Pending	South Africa	2018/05852	3/8/2017		Maverick Therapeutics, Inc.
Pending	South Africa	2020/02325	9/6/2018		Maverick Therapeutics, Inc.
Pending	Taiwan	106107861	3/8/2017		Maverick Therapeutics, Inc.
Pending	Taiwan	107131542	9/6/2018		Maverick Therapeutics, Inc.

Schedule A

Status	Country	Application No	Filing Date	Patent No	Assignor
Pending	Thailand	1801005351	3/8/2017		Maverick Therapeutics, Inc.
Pending	Thailand	2001001329	9/6/2018		Maverick Therapeutics, Inc.
Pending	Ukraine	a2018.09966	3/8/2017		Maverick Therapeutics, Inc.
Pending	Ukraine	a202002266	9/6/2018		Maverick Therapeutics, Inc.
Pending	USA	63/074,699	9/4/2020		Maverick Therapeutics, Inc.
Pending	USA	63/066,565	8/17/2020		Maverick Therapeutics, Inc.
Pending	USA	63/125,267	12/14/2020		Maverick Therapeutics, Inc.
Pending	USA	63/171,556	4/6/2021		Maverick Therapeutics, Inc.
Inactive	USA	62/555,999	9/8/2017		Maverick Therapeutics, Inc.
Inactive	USA	62/555,943	9/8/2017		Maverick Therapeutics, Inc.
Inactive	USA	62/586,627	11/15/2017		Maverick Therapeutics, Inc.
Inactive	USA	62/587,318	11/16/2017		Maverick Therapeutics, Inc.
Inactive	USA	62/716,755	8/9/2018		Maverick Therapeutics, Inc.
Inactive	USA	62/814,159	3/5/2019		Maverick Therapeutics, Inc.
Inactive	USA	62/814,210	3/5/2019		Maverick Therapeutics, Inc.
Inactive	USA	62/826,523	3/29/2019		Maverick Therapeutics, Inc.
Inactive	USA	62/814,744	3/6/2019		Maverick Therapeutics, Inc.
Inactive	USA	62/305,092	3/8/2016		Maverick Therapeutics, Inc.
Inactive	USA	62/946,292	12/10/2019		Maverick Therapeutics, Inc.
Inactive	USA	63/048,474	7/6/2020		Maverick Therapeutics, Inc.
Pending	USA	15/727,423	3/8/2017		Maverick Therapeutics, Inc.
Pending	USA	16/124,556	9/6/2018		Maverick Therapeutics, Inc.
Pending	USA	17/266,065	8/9/2019		Maverick Therapeutics, Inc.
Pending	USA	16/810,770	3/5/2020		Maverick Therapeutics, Inc.
Inactive	USA	16/645,237	9/6/2018		Maverick Therapeutics, Inc.

Schedule A

Status	Country	Application No	Filed Date	Patent No	Assignor
Pending	Venezuela	2019-000315	9/6/2018		Maverick Therapeutics, Inc.
Pending	Vietnam	1-2018-04368	3/8/2017		Maverick Therapeutics, Inc.
Pending	Vietnam	1-2020-01951	9/6/2018		Maverick Therapeutics, Inc.
Pending	WIPO	PCT/US20/21276	3/5/2020		Maverick Therapeutics, Inc.
Pending	WIPO	PCT/US20/21270	3/5/2020		Maverick Therapeutics, Inc.
Inactive	WIPO	PCT/US17/21435	3/8/2017		Maverick Therapeutics, Inc.
Inactive	WIPO	PCT/US18/49798	9/6/2018		Maverick Therapeutics, Inc.
Inactive	WIPO	PCT/US18/49774	9/6/2018		Maverick Therapeutics, Inc.
Inactive	WIPO	PCT/US19/45918	8/9/2019		Maverick Therapeutics, Inc.